# A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct04641754/  
OnCo record `nct04641754` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Iruplinalkib in Non-small-cell lung cancer, run by Qilu Pharmaceutical Co., Ltd., with a status the registry has not verified recently.

## Summary

A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT04641754 by Qilu Pharmaceutical Co., Ltd., with 176 participants planned, started 2019-03-07 and due to reach its primary completion in 2020-12. Interventions recorded: WX-0593 Tablets. Conditions recorded: Non-small Cell Lung Cancer.

Linked to the drug Iruplinalkib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04641754
- Phase: 2
- Setting: Phase II Clinical Study to Evaluate the Efficacy and Safety of WX-0593 in Patients With Crizotinib-resistant ALK -Positive, or Crizotinib-resistant/Crizotinib-naive ROS1-positive Non-small Cell Lung Cancer (NSCLC)
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Enrolled: 176

## Sources

- ClinicalTrials.gov NCT04641754: https://clinicaltrials.gov/study/NCT04641754

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Iruplinalkib](https://onco.cc/drugs/iruplinalkib/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct04641754.json